

# MicroRNA-29b mediates altered innate immune development in acute leukemia

Bethany L. Mundy-Bosse,<sup>1</sup> Steven D. Scoville,<sup>2</sup> Li Chen,<sup>1</sup> Kathleen McConnell,<sup>1</sup> Hsiaoyin C. Mao,<sup>1</sup> Elshafa H. Ahmed,<sup>1</sup> Nicholas Zorko,<sup>3</sup> Sophia Harvey,<sup>4</sup> Jordan Cole,<sup>5</sup> Xiaoli Zhang,<sup>6</sup> Stefan Costinean,<sup>7</sup> Carlo M. Croce,<sup>8,9</sup> Karilyn Larkin,<sup>1</sup> John C. Byrd,<sup>1,9</sup> Sumithira Vasu,<sup>1,9</sup> William Blum,<sup>1,9</sup> Jianhua Yu,<sup>1,9</sup> Aharon G. Freud,<sup>9,10</sup> and Michael A. Caligiuri<sup>1,9</sup>

<sup>1</sup>Division of Hematology, Department of Internal Medicine, <sup>2</sup>Biomedical Sciences Graduate Program, Medical Scientist Training Program, and <sup>3</sup>Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA. <sup>4</sup>Michigan State University College of Human Medicine, Lansing, Michigan, USA. <sup>5</sup>The Ohio State University, College of Medicine, and <sup>6</sup>Center for Biostatistics, Columbus, Ohio, USA. <sup>7</sup>Department of Pathology and Microbiology, and <sup>8</sup>Department of Molecular Virology, Immunology and Medical Genetics, University of Nebraska College of Medicine, Lincoln, Nebraska, USA. <sup>9</sup>Comprehensive Cancer Center, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio, USA. <sup>10</sup>Department of Pathology, University of Nebraska College of Medicine, Lincoln, Nebraska, USA.

**Natural killer (NK) cells can have potent antileukemic activity following haplo-mismatched, T cell-depleted stem cell transplantations for the treatment of acute myeloid leukemia (AML), but they are not successful in eradicating de novo AML. Here, we have used a mouse model of de novo AML to elucidate the mechanisms by which AML evades NK cell surveillance. NK cells in leukemic mice displayed a marked reduction in the cytolytic granules perforin and granzyme B. Further, as AML progressed, we noted the selective loss of an immature subset of NK cells in leukemic mice and in AML patients. This absence was not due to elimination by cell death or selective reduction in proliferation, but rather to the result of a block in NK cell differentiation. Indeed, NK cells from leukemic mice and humans with AML showed lower levels of TBET and EOMES, transcription factors that are critical for terminal NK cell differentiation. Further, the microRNA miR-29b, a regulator of T-bet and EOMES, was elevated in leukemic NK cells. Finally, deletion of miR-29b in NK cells reversed the depletion of this NK cell subset in leukemic mice. These results indicate that leukemic evasion of NK cell surveillance occurs through miR-mediated dysregulation of lymphocyte development, representing an additional mechanism of immune escape in cancer.**

## Introduction

Acute myeloid leukemia (AML) is one of the most common types of leukemia diagnosed in adults. While many advancements have been made in the understanding of the genetic components of AML, the 5-year survival rate for all types of AML is still less than 25% (1). There is a clear need for improved therapeutics and a more complete understanding of how AML escapes our natural defenses and renders the immune system incapable of controlling leukemia. Natural killer (NK) cells are large granular lymphocytes that are a key component of innate immunity. Under homeostatic conditions, they represent 5%–15% of peripheral blood mononuclear cells, and are constant immune surveyors of malignancy in circulation and lymphoid tissue (2). While NK cells exhibit a potent clinical effect against AML in certain settings of T cell-depleted, haploidentical transplantation, success has not been seen in de novo AML, and immune evasion is a critical barrier to obtaining long-term disease-free survival (3, 4).

Multiple mechanisms of innate immune escape have been previously described in AML patients, including decreased NK cytotoxicity receptor (NCR) expression, increased inhibitory NKG2A expression, downregulation of NK-activating ligands, and secretion of soluble NK-inhibitory factors (5–10). These mecha-


nisms likely work in concert to render both autologous and transplanted NK cells ineffective at controlling AML blast outgrowth over time (3, 11). Targeting individual immune defects has been shown to provide limited long-term improvement to certain cancer patients, and likely indicates that additional unknown mechanisms of immune evasion are in operation allowing for successful outgrowth of AML stem cells and blasts (12–16). While the mechanisms of innate immune evasion to date have involved circumventing mature cytolytic NK cells (5–10), assessment of NK cell development in the leukemic environment has not been explored.

Murine NK cells develop from common lymphoid progenitors in the bone marrow, where there is the potential for both physical interactions with AML stem cells and blasts and exposure to soluble factors produced by these tumor cells. The mouse NK1.1<sup>+</sup>CD3<sup>-</sup> NK cell population is subdivided into 4 stages of NK cell development based on the surface expression of CD27 and CD11b, going from least mature to most mature: CD27<sup>-</sup>CD11b<sup>-</sup>→CD27<sup>+</sup>CD11b<sup>-</sup>→CD27<sup>+</sup>CD11b<sup>+</sup>→CD27<sup>-</sup>CD11b<sup>+</sup> (17, 18). These surface antigens identify distinct functional subsets. Human NK cells develop from lymphoid precursors in secondary lymphoid tissue and proceed through a discrete 5-stage development pathway, culminating in mature NK cells that lack CD3 and have low-density expression of the adhesion molecule CD56 (CD56<sup>dim</sup>) (2, 19, 20). The CD3<sup>-</sup>CD56<sup>bright</sup> subset of NK cells represent a less mature population in lymphoid tissue and blood, in that they produce higher levels of inflammatory cytokines with little or no natural cytotoxicity (2).

**Conflict of interest:** The authors have declared that no conflict of interest exists.

**Submitted:** November 6, 2015; **Accepted:** September 15, 2016.

**Reference information:** *J Clin Invest.* 2016;126(12):4404–4416. doi:10.1172/JCI85413.



**Figure 1. Role of the immune system in PTD/ITD model of AML. (A)** Survival of PTD/ITD primary mice compared with PTD/ITD/Rag GC KO ( $***P < 0.0001$ ;  $n = 12$  PTD/ITD,  $n = 5$  PTD/ITD/Rag GC KO). A log-rank test was used for statistical analysis. **(B)** CD45.2<sup>+</sup> AML blasts were transplanted into congenic CD45.1<sup>+</sup> recipients with or without WT NK cells. The percentage of circulating blasts (CD45.2<sup>+</sup>) was evaluated by flow cytometry ( $P = 0.012$ ;  $n = 4$ /group, 2 independent studies with a representative study depicted; 2-sample  $t$  test).  $*P = 0.012$ .

While the phenotypic surface marker expression varies, the process of NK cell development in both humans and mice is tightly controlled by transcription factors that can be activated in response to cytokine stimulation and/or additional activating signals. Two key transcriptional regulators of NK cell development are T-box-related TBX21 (TBET) and eomesodermin (EOMES); these 2 transcription factors work in concert to control the final stages of NK cell differentiation in humans and mice (21, 22). Indeed, mice that are genetically altered to inhibit expression of both TBET and EOMES lack mature NK cells (22). Recently, microRNAs (miRs) have also emerged as important regulators of immune cell development and function (23–26), and the modulation of TBET and EOMES has been linked to miR-29b in T cell studies (23, 27). To date, the importance of miR regulation of NK cell development in the setting of cancer has not been evaluated.


In the current study we show that AML is impeded early in the disease process by NK cells. With progression of AML there is a significant reduction in NK cell perforin, and a selective loss of an immature NK cell subset secondary to a deregulation of a microRNA that regulates NK cell development.

## Results

**Immune cells mediate AML progression.** Primary mice harboring both the mixed-lineage leukemia (MLL) partial tandem duplication ( $Mll^{PTD/WT}$ ) and the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication ( $Flt3^{ITD/WT}$ ) mutations (termed PTD/ITD mice) develop de novo AML with 100% penetrance (28). These PTD/ITD mice were crossed with  $Rag2^{-/-} Il2rg^{-/-}$  mice to produce PTD/ITD/Rag GC KO mice; all died from leukemia as validated

by elevated wbc count and/or histological confirmation by a pathologist (data not shown). PTD/ITD/Rag GC KO mice had significantly reduced survival times as compared with PTD/ITD mice (Figure 1A;  $P < 0.0001$ ), suggesting the immune system plays a role in the progression of AML in the PTD/ITD murine model. Since the Rag GC KO mice lack T, B, and NK cells, we next sought to determine whether NK cells, specifically, could slow AML progression. We adoptively transferred WT NK cells with CD45.2<sup>+</sup> leukemic blasts into irradiated WT CD45.1<sup>+</sup> congenic recipient mice. The same absolute number of AML (CD45.2<sup>+</sup>) blasts were infused into both sets of recipient mice, and the percentage of circulating AML blasts in mice that received WT NK and AML blasts was compared with that in mice that received only AML blasts. There was a significant reduction in circulating AML blasts at 21 days after transfer in the mice that received NK cells along with the AML blasts, as compared with mice that received AML blasts only (Figure 1B;  $P = 0.012$ ). Intriguingly, these mice had no overall improvement in survival time, indicating that while the NK cells are initially effective at slowing progression, as indicated by reduced CD45.2<sup>+</sup> circulating AML blasts, the leukemic environment may support innate immune cell evasion as the disease progresses. Like blood, examination of the bone marrow also showed reduced AML blast infiltration, while the spleen did not (not shown). Thus, it is also possible that persistent disease in certain organ sites could account for similar overall survival curves.

**NK cell function and homeostasis are altered in leukemic mice.** After determining that NK cells were initially effective at modulating AML outgrowth but did not improve overall survival, we evaluated NK cell activity in the setting of AML. A hallmark of NK cell function is the ability to recognize and lyse tumor targets; thus, both autologous blasts and tumor cell lines were used as targets to assess the cytotoxicity of NK cells from leukemic mice. Autologous leukemic blasts were transplanted into congenic WT CD45.1<sup>+</sup> recipients, and leukemia was allowed to develop. This transplant model was used for all studies unless otherwise noted to ensure that NK cells being evaluated were of normal CD45.1<sup>+</sup> origin, and therefore did not contain the *Mll*-PTD or *Flt3*-ITD mutations. Once wbc counts were greater than 100,000/ $\mu$ l, mice were euthanized and NK cells and leukemic blasts were harvested from the spleen. As has been reported previously in AML patients (29–31), NK cell killing of autologous blasts was minimal, although the same NK cells were able to lyse Yac-1 and C1498 cell targets at levels comparable to those of nonleukemic control NK cells (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI85413DS1). To determine whether alterations in autologous killing could be linked to NK cell intrinsic factors in vivo, the level of perforin was evaluated in NK cells freshly isolated from nonleukemic and leukemic mice. We discovered that total perforin protein and granzyme B expression levels were significantly decreased in NK cells from leukemic mice (Figure 2A;  $P = 0.006$ ; Figure 2B;  $P = 0.046$ ). Baseline expression of granzyme B by intracellular flow cytometric analysis was not detected in NK cells in either leukemic or nonleukemic mice. Intracellular IFN- $\gamma$  production was also evaluated in NK cells cultured ex vivo from nonleukemic and leukemic mice with and without stimulation. NK cells from leukemic mice that were stimulated through plate-bound NK1.1 showed a significant reduction in intracellular IFN- $\gamma$  production compared with NK




**Figure 2. NK cell activity is altered in leukemic mice.** (A) Perforin protein expression was evaluated in freshly isolated splenic NK cells by flow cytometry ( $n = 5/\text{group}$ ;  $**P = 0.006$ ). (B) Granzyme B expression was measured by real-time RT-PCR on FACS-isolated NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells ( $*P = 0.02$ ;  $n = 3$  mice per group, repeated 2 independent times with a representative study depicted). (C) Splenocytes were activated with anti-NK1.1 (15  $\mu\text{g}/\text{ml}$ ) or isotype control; labeled with anti-NK1.1, -CD3, and -CD45.1 surface antibodies; then fixed, permeabilized, and labeled with anti-IFN- $\gamma$  antibody and evaluated by flow cytometry ( $***P = 0.004$ ;  $n = 3$  mice per group, 2 independent studies, representative figure shown). Student's *t* test was used. (D) Proliferation was evaluated with Ki67 staining in freshly isolated splenic NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells by flow cytometry ( $***P = 0.0001$ ;  $n = 4/\text{group}$ , repeated 3 independent times with a representative donor depicted). (E) Nonleukemic or leukemic mice were injected with 0.5  $\mu\text{g}$  IL-15. After 24 hours, organs were harvested, and proliferation was evaluated with Cell Proliferation Dye eFluor 670 within the NK1.1<sup>+</sup>CD3<sup>-</sup> cell population by flow cytometry ( $P < 0.01$  for all organs;  $n = 4/\text{group}$ ). (F) Absolute number of NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells in freshly isolated spleen, blood, and bone marrow (BM) of WT or leukemic mice ( $**P < 0.001$ ,  $***P < 0.0001$ ;  $n = 5\text{--}10$  mice per group). Student's *t* test was used for single comparisons; linear mixed effects models with Holm's adjustment were used for multiple comparisons within the same mice.

cells from nonleukemic mice (Figure 2C;  $P = 0.004$ ). Soluble IFN- $\gamma$  production was also evaluated in NK cells cultured *ex vivo* from nonleukemic and leukemic mice with and without stimulation with IL-12 and IL-18 for 24 hours. Interestingly, NK cells isolated from leukemic mice had significantly elevated IFN- $\gamma$  upon stimulation as compared with NK cells from nonleukemic mice (Supplemental Figure 2). Splenic NK cell proliferation was next evaluated in nonleukemic and leukemic mice by flow cytometry. NK cells from leukemic mice exhibited significantly less proliferation as compared with NK cells harvested from nonleukemic mice (Figure 2D;  $P < 0.0001$ ). To determine whether NK cells were responsive to external proliferative stimulation, IL-15 was injected into nonleukemic or leukemic mice, and cells were evaluated for proliferation 24 hours later. In all organs evaluated, proliferation was significantly decreased in the NK cells from leukemic mice as compared with NK cells in the nonleukemic mice (Figure 2E;  $P < 0.01$ , all organs). Overall these results suggest that NK cell activity is reduced in mice with progressive leukemia, with the exception of cytokine-stimulated NK cell production of IFN- $\gamma$ .

Once it was determined that NK cells in leukemic mice exhibited alterations in phenotype and function, we then evaluated

what impact the leukemic environment might have on NK cell homeostasis. While NK cell percentages were reduced in leukemic bone marrow, lymph nodes, spleen, and blood (data not shown), the absolute numbers of NK cells differed between compartments. Compared with nonleukemic mice, absolute numbers were increased in the blood, not significantly different in the spleen, although greatly reduced in the bone marrow and lymph nodes of leukemic mice (Figure 2F and data not shown).

*NK cell maturation is altered in leukemic mice.* Using the transplant model, we next assessed the NK cell developmental subsets found in leukemic mice and compared them with those in nonleukemic mice. Previous studies established a progression of NK maturation based on the surface expression of CD27 and CD11b among the total pool of CD3<sup>+</sup>NK1.1<sup>+</sup> NK cells, as reviewed above (17, 18). We noted a striking and highly significant reduction in the CD27 and CD11b double-positive (DP) splenic NK cell subset in the leukemic mice compared with the nonleukemic mice (Figure 3, A and B;  $***P < 0.0001$ ). In contrast, we noted the leukemic mice had a significant increase in the less mature CD27<sup>+</sup>CD11b<sup>-</sup> NK cell subsets (Figure 3, A and B;  $**P = 0.0009$ ), while the most mature CD27<sup>-</sup>CD11b<sup>+</sup> showed no significant change. There was also a significant reduc-




**Figure 3. Mature NK cell populations are altered in leukemic mice.** Freshly isolated splenocytes from nonleukemic or leukemic mice in the transplant model were labeled with anti-NK1.1, -CD3, -CD45.1, -CD27, and -CD11b and evaluated by flow cytometry. (A) Dot plots represent nonleukemic or leukemic splenocytes after gating on NK1.1<sup>+</sup>CD3<sup>+</sup>CD45.1<sup>+</sup> cells. Percentages indicate the CD27<sup>+</sup>CD11b<sup>+</sup> NK cell population in relation to total NK1.1<sup>+</sup>CD3<sup>+</sup>CD45.1<sup>+</sup> cells. (B) Percentages of all 4 NK1.1<sup>+</sup>CD3<sup>+</sup> NK cell populations as determined by CD11b and CD27 expression (\*\* $P = 0.0009$ , \*\*\* $P < 0.0001$ ;  $n = 21$  WT and  $n = 23$  AML, 4 independent experiments). (C) Cells were isolated from spleen, bone marrow, blood, and lymph nodes (LN), labeled with anti-NK1.1, -CD3, -CD45.1, -CD27, and -CD11b, and evaluated by flow cytometry. CD27<sup>+</sup>CD11b<sup>+</sup> DP NK cell percentages from each organ are depicted (\*\*\* $P < 0.001$ ;  $n =$  minimum 4/group, representative figure from 2 independent studies). (D) The percentage of CD27<sup>+</sup>CD11b<sup>+</sup> NK cells was evaluated by flow cytometry in the blood of nonleukemic or leukemic mice at the indicated days after AML transplant (\*\*\* $P = 0.0005$ ;  $n = 3$ /group, 2 independent studies with a representative study depicted). (E) Freshly isolated splenocytes were labeled with anti-NK1.1, -CD3, and -CD45.1 surface antibodies, then fixed, permeabilized, and labeled with anti-EOMES antibody and evaluated by flow cytometry. Total NK1.1<sup>+</sup>CD3<sup>+</sup> NK cells and mature NK cell subsets analyzed for EOMES expression (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ;  $n = 6$  mice per group, representative figure from 3 independent studies). Linear mixed-effects models were used for multiple comparisons with Holm's adjustment.

tion in the absolute number of DP NK cells in spleen, bone marrow, and blood of leukemic mice as compared with NK cells of nonleukemic mice ( $P < 0.0001$ ; Supplemental Figure 3). The selective loss of DP NK cells was next observed in primary PTD/ITD mice once they developed de novo AML, but not in mice harboring the single PTD or single ITD mutation, which do not develop AML (Supplemental Figure 4A). Finally, we evaluated the surface expression of KLRG1, an additional marker of NK cell maturation on CD11b<sup>+</sup> NK cells, and observed a significant downregulation of KLRG1 in bulk splenic NK cells (Supplemental Figure 4B and refs. 32, 33). To validate that

the selective loss in CD27<sup>+</sup>CD11b<sup>+</sup> DP NK cells was not limited to the spleen in the transplant and de novo AML mouse models, we evaluated blood, bone marrow, and lymph node samples in both models. All organs had significantly reduced percentages of DP NK cells (Figure 3C;  $P < 0.0001$ , all organs). When blood was sampled at multiple time points after AML transplant, it was discovered that the DP NK cell population decreased as the AML burden increased in the mice. By 28 days, all leukemic mice had wbc counts over 100,000/ $\mu$ l and a highly significant difference in the DP NK cell subset when compared with nonleukemic mice (Figure 3D; \*\*\* $P = 0.0005$ ). Intriguingly, when the levels of EOMES were evaluated in the developmental NK cell subsets, there was reduced EOMES overall in the NK cells of leukemic mice, but there was also a reduction in the fraction of cells expressing EOMES within each developmental NK cell subset after the acquisition of CD27 in leukemic mice as compared with identical developmental NK cell subsets from nonleukemic mice (Figure 3E; \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ; and Supplemental Figure 5A). The levels of both EOMES and TBX21 (T-bet) protein expression, as measured by the mean fluorescence intensity, were significantly decreased in bulk NK cells from leukemic mice and in each of their subsets except the most immature CD27<sup>-</sup>CD11b<sup>-</sup> subset (data not shown and Supplemental Figure 5B; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ). Interestingly, the most mature CD27<sup>+</sup>CD11b<sup>+</sup> NK cell subset in leukemic mice was still present at levels seen in nonleukemic

mice. When we evaluated the critical cytolytic granule perforin in both the DP and the more mature CD27<sup>+</sup>CD11b<sup>+</sup> NK cell subsets found in leukemic mice, there was a reduction in both the percentage of cells expressing perforin and the amount expressed per cell as measured by mean fluorescence intensity, when compared with identical NK subsets found in nonleukemic mice (Figure 4, A and B; \* $P = 0.04$ , \*\* $P = 0.004$ , \*\*\* $P < 0.001$ ).

*In vivo NK cell adoptive transfer results in selective loss of the DP NK cell subset.* The above-noted studies evaluated defects in endogenous NK cells that had developed during the progression




**Figure 4. Cytolytic perforin expression is decreased in CD11b<sup>+</sup> NK cell subsets in leukemic mice.** (A) The percentage of perforin in splenic DP or CD27<sup>+</sup>CD11b<sup>+</sup> NK cells was determined (\*\* $P = 0.004$ , \*\*\* $P < 0.001$ ;  $n = 5$ /group, 2 independent studies with a representative study depicted). (B) Level of protein expression of perforin in splenic DP or CD27<sup>+</sup>CD11b<sup>+</sup> NK cells, expressed as MFI (\* $P = 0.04$ , \*\*\* $P < 0.001$ ;  $n = 5$  mice per group, 2 independent studies with a representative study depicted). Student's  $t$  test was used for single comparisons.

of AML. We next sought to determine whether we would see the same selective depletion of the DP NK cell subset when naive WT NK cells were transferred into leukemic mice. Bulk NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells isolated to greater than 98% purity by FACS were transferred into either leukemic mice or nonleukemic controls. Within 1 week, mice had a significant and selective loss in the DP NK cell subset (Figure 5A;  $P = 0.031$ ). To determine whether this loss was due to an increase in apoptosis, the experiment was repeated and the mice were evaluated for in vivo apoptosis in leukemic and nonleukemic mice. In fact, at 48 hours there was a significantly lower fraction of DP NK cells undergoing apoptosis in the leukemic mice compared with the nonleukemic mice (Figure 5B;  $P = 0.005$ ). The CD27<sup>+</sup>CD11b<sup>+</sup> DP NK cell population was also isolated by FACS and adoptively transferred into either leukemic or nonleukemic control mice for in vivo evaluation of apoptosis. In agreement with the results of the bulk NK cell transfer, there was a small but significant reduction in apoptosis in the DP NK cells that were transplanted into the leukemic mice compared with the nonleukemic mice (Supplemental Figure 6). Since a reduction in proliferation was previously observed with bulk NK cells in leukemic mice, we also evaluated the proliferative capacity of transplanted DP NK cells. WT DP NK cells transferred into leukemic mice had significantly lower levels of proliferation 48 hours after adoptive transfer as compared with WT DP NK cells transferred into nonleukemic mice ( $P = 0.0004$ ; Figure 5C), indicating that this defect occurs quickly upon NK cell transfer into leukemic mice. However, the proliferative capacity of the DP NK cell subset alone was not significantly different from that seen among total NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells in leu-

kemic mice (Figure 2D), indicating that this process did not significantly contribute to the selective depletion of this NK cell subset.

*Transfer of NK cell developmental intermediates identifies a block in maturation.* After determining that the endogenous DP NK cells were selectively reduced in leukemic mice and exogenous DP NK cells were selectively depleted after adoptive transfer into leukemic mice without a selective increase in apoptosis or decrease in proliferation, we sought additional explanations for the reduction. While leukemic mice exhibited a significant reduction in CD27<sup>+</sup>CD11b<sup>+</sup> DP NK cells, they also had significantly elevated levels of the CD27<sup>+</sup>CD11b<sup>-</sup> immature NK cell subset, the upstream NK cell precursor population (Figure 3B;  $P = 0.0009$ ). We hypothesized that NK cells were blocked at the CD27<sup>+</sup>CD11b<sup>-</sup> stage of NK cell maturation in the leukemic mice. To test this, we isolated only CD27<sup>+</sup>CD11b<sup>-</sup> NK cells, as indicated in the red box on the flow cytometry dot plot (Figure 5D, left), and transplanted these precursor NK cells into leukemic or nonleukemic mice. Importantly, we saw an elevated percentage of the CD27<sup>+</sup>CD11b<sup>-</sup> NK cell precursor in the leukemic mice as compared with the nonleukemic mice within 1 week of the adoptive transfer (Figure 5D;  $P < 0.0001$ , all populations). Further, we saw a significantly lower fraction of CD27<sup>+</sup>CD11b<sup>+</sup> DP NK cells emerge in the leukemic mice compared with the nonleukemic mice (Figure 5D;  $P < 0.0001$ ). These results indicate a blockage in maturation at the CD27<sup>+</sup>CD11b<sup>-</sup> stage of NK cell maturation in leukemic mice.

*Forced overexpression of T-bet and EOMES via the genetic deletion of Mir29b restores CD27<sup>+</sup>CD11b<sup>+</sup> NK cell population in vivo.* After identifying a developmental block in NK cell development found in the PTD/ITD AML mouse model, we next sought to determine what mechanism might be responsible for this selective depletion of the developmental intermediate (DP) NK cell population. With the data demonstrating reduced T-bet and EOMES expression in NK cells taken from leukemic mice, we hypothesized that a single regulator of both transcription factors may be the target in the leukemic environment, thereby preventing normal NK cell maturation. The microRNA miR-29b has been previously demonstrated to target and regulate both T-bet and EOMES directly in T cells (23, 27). The level of *Mir29b* was measured by quantitative real-time RT-PCR and found to be significantly elevated in bulk NK cells and CD11b<sup>+</sup> NK cell subsets taken from leukemic mice as compared with NK cells taken from nonleukemic mice (Figure 6A;  $P = 0.009$ ; and Supplemental Figure 7). We therefore wanted to determine whether genetic disruption of the miR-29b loci would increase expression of T-bet and EOMES in the NK cell compartment, and whether the adoptive transfer of miR-29b-deficient NK cells could rescue the DP NK cell subset that is selectively depleted in leukemic mice. NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells from C57BL/6 *Mir29ab1*<sup>-/-</sup> mice (hereafter referred to as miR-29b KO mice) or WT littermate control mice were FACS sorted to greater than 99% purity; the former showed near-complete absence of miR-29b expression (data not shown) and higher expression of both T-bet and EOMES when compared with their WT controls by quantitative real-time RT-PCR before transfer into the recipient mice (Figure 6B). It is still possible that the relationship between miR-29b and T-bet and EOMES in NK cells occurs via an indirect mechanism; however, in this model we do see lower levels of both transcription factors in the presence of elevated miR-29b in the NK cells of leukemic mice.




**Figure 5. NK cells exhibit block in NK cell maturation.** NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells ( $3 \times 10^5$ ) were isolated from spleens of WT congenic CD45.1<sup>+</sup> mice and adoptively transferred into nonleukemic or leukemic mice. At various time points, spleens were harvested, and cells were labeled with anti-NK1.1, -CD3, -CD45.1, -CD27, and -CD11b and evaluated by flow cytometry. (A) Transplanted NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells (population highlighted in dot plot in red box) were harvested after 7 days and evaluated for NK maturation by flow cytometry (\*\* $P = 0.031$ ;  $n = 4$  mice per group, 2 independent studies with a representative study depicted). (B) CD27<sup>+</sup>CD11b<sup>-</sup> DP splenic NK cells were harvested 3 days after adoptive transfer of NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells and evaluated for apoptosis using FLIVO in vivo imaging dye (\*\* $P = 0.005$ ;  $n = 3$ /group). (C) NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells were labeled with Cell Proliferation Dye eFluor 670 before adoptive transfer. Seven days after adoptive transfer, the percentage of proliferating splenic CD27<sup>+</sup>CD11b<sup>-</sup> NK cells was determined by flow cytometry, gating on peaks indicating cell division (\*\* $P = 0.0004$ ;  $n = 6$  mice per group, 2 independent studies). (D) NK1.1<sup>+</sup>CD3<sup>-</sup>CD27<sup>+</sup>CD11b<sup>-</sup> NK cells ( $2 \times 10^5$ , as indicated in the red box) were isolated from spleens of WT congenic CD45.1<sup>+</sup> mice and adoptively transferred into nonleukemic or leukemic mice. After 7 days, spleens were harvested, and cells were labeled with anti-NK1.1, -CD3, -CD45.1, -CD27, and -CD11b and evaluated by flow cytometry (\*\* $P < 0.0001$ , all populations;  $n = 4$  mice per group, 2 independent studies). Student's *t* test was used for single comparisons; linear mixed effects models with Holm's adjustment were used for multiple comparisons within the same mice.

Next, equal numbers of FACS-sorted NK1.1<sup>+</sup>CD3<sup>-</sup> NK cells from WT littermate control or miR-29b KO mice were adoptively transferred into WT or leukemic recipient mice. Consistent with our previous experiments, the DP population of NK cells from WT donor mice was reduced in recipient leukemic mice compared with nonleukemic mice after 7 days (Figure 6C, left; \* $P = 0.02$ ). In contrast, the proportion of the DP donor NK cells isolated from miR-29b KO mice was the same regardless of recipient status (leukemic or nonleukemic) (Figure 6C, right;  $P = \text{NS}$ ). In addition, while there was no noticeable change in T-bet expression, there was a significant increase in the level of EOMES protein expression in the miR-29b KO NK cells in the leukemic mice after transfer as compared with the transferred WT littermate NK cells (Figure 6D;  $P = 0.01$ ). Thus, miR-29b KO NK cells were resistant to the loss of the CD27<sup>+</sup>CD11b<sup>-</sup> DP NK cell population in leukemic mice in vivo. To determine whether miR-29b KO NK cells could slow AML progression, we adoptively transferred NK cells from miR-29b KO transgenic mice or WT littermate control mice along with leukemic blasts into irradiated WT CD45.1<sup>+</sup> congenic recipient mice. The same absolute number of AML (CD45.2<sup>+</sup>) blasts was infused into both sets of recipient mice, and the percentage of circulating AML blasts in mice that received miR-29b KO NK cells and AML blasts was compared with that in mice that received WT NK cells and AML blasts. There was a trend toward reduced circulating AML blasts at 21 days after transfer and a significant reduction in wbc count in the mice that received miR-29b KO NK cells along

with the AML blasts, as compared with mice who received WT NK cells along with the AML blasts (Supplemental Figure 8, A and B;  $P = 0.02$ ). In addition, there was a trend to improved overall survival in the leukemic mice that received miR-29b KO NK cells as compared with the leukemic mice that received WT NK cells (Supplemental Figure 8C;  $P = 0.06$ ). Together, these data suggest that miR-29b in NK cells may play a role in modulating AML progression.

**Reduction of an NK cell intermediate in AML patients.** We next sought to determine whether a similar blockade in NK cell development occurs in patients with AML. Untreated patients with newly diagnosed AML provided blood samples that were compared with normal donor samples matched for age and sex. Importantly, we discovered that AML patients have a significant reduction in the less mature, CD56<sup>bright</sup> NK cell subset, i.e., the Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> NK cell subset, when compared with normal donors (Figure 7, A and B; \*\*\* $P < 0.0001$ ). These results indicate that NK cell maturation is altered in a majority of AML patients. To confirm a block in NK cell maturation, we again evaluated the protein expression of TBET and EOMES in the Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> NK cell subset. There was a trend toward reduced EOMES expression (Supplemental Figure 9;  $P = 0.24$ ), and significantly reduced T-bet expression (Figure 7C;  $P < 0.0001$ ), in Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> NK cells from AML patients when compared with the same NK cell subset found in normal donors. Finally, the CD56<sup>bright</sup> NK cell subset that is reduced in AML patients was isolated by FACS to a purity greater than 99%, and the level of *Mir29b*



**Figure 6. miR-29b is dysregulated in leukemic NK cells, and modulation of miR-29b in NK cells restores CD27<sup>+</sup>CD11b<sup>+</sup> NK cells in vivo.** (A) NK1.1<sup>+</sup>CD3<sup>-</sup> splenic NK cells were isolated by FACS from nonleukemic or leukemic mice, and levels of *Mir29b* were evaluated by quantitative real-time RT-PCR ( $n = 3$  mice per group; 3 independent studies with a representative study depicted).  $**P = 0.009$ . (B) NK1.1<sup>+</sup>CD3<sup>-</sup> splenic NK cells were isolated from miR-29b KO or WT littermate control mice, and levels of *T-bet* and *Eomes* expression were evaluated by quantitative real-time RT-PCR preinjection. Representative data from 2 independent experiments. (C) Schematic depicts splenic NK cells (red box) isolated from miR-29b KO or WT littermate control mice that were equally split and transferred into WT and leukemic recipients. After 7 days, splenocytes were harvested and labeled with anti-NK1.1, -CD3, -CD27, and -CD11b. Data are presented as a ratio of donor DP% (WT or AML) normalized to the donor DP% found in WT recipient conditions ( $*P = 0.02$ ;  $n = 4$  mice per group). (D) The level of EOMES protein expression was determined by measurement of MFI in the NK cells adoptively transferred from miR-29b KO or WT littermate control mice into leukemic recipients ( $**P = 0.01$ ). The Student's *t* test was used for single comparisons, with Holm's adjustment for multiple comparisons between groups.


was measured by quantitative real-time RT-PCR. There was a significant increase in *Mir29b* expression in the CD56<sup>bright</sup> NK cell population in AML patients as compared with normal donor controls ( $P = 0.006$ ; Figure 7D). These results suggest that a mechanism of innate immune evasion comparable to that discovered in our mouse model of AML may occur in AML patients.

## Discussion

Multiple mechanisms that enable AML to evade mature NK cell surveillance have been previously identified (5–10, 34). NK cells in AML patients can have a reduction in NKP30-, NKP44-, and

NKP46-activating receptors that can lead to decreased NK cell cytotoxicity against AML blasts (8, 29, 30, 35). The inhibitory receptor NKG2A has also been demonstrated to be upregulated on NK cells from AML patients, and is associated with failure to reach remission (34). Additionally, AML blasts can evade NK cells by shedding activating stress ligands such as MICA and MICB, which, once soluble, can activate NK cell activity away from the actual tumor cell and lead to innate immune exhaustion (9, 36). Interestingly, it was noted by Costello et al. that even when autologous NK cells or normal allogeneic NK cells maintained expression of these receptors and other natural cytotoxicity receptors (NCRs), the NK cells were still unable to effectively lyse primary tumor targets *ex vivo*, indicating that additional mechanisms of inherent immune evasion are operative in the AML blasts (29). Despite understanding of several mechanisms of mature NK cell dysfunction during the progression of AML, a complete understanding of this process has not yet been attained. Further defining the mechanisms of innate immune evasion in the leukemic environment will be critical to developing effective treatment strategies that address these defects and favorably alter the outcome for AML patients.

In this report, we first asked whether NK cells could delay the onset or progression of AML by using an immunocompetent mouse model of *de novo* AML. Through observation, cross-breeding, and adoptive transfer experiments we learned that AML occurs earlier and has a much more rapidly fatal course in the absence of T, B, and NK cells. Further, we showed that the NK cell itself has a significant role in delaying the early progression of this disease. However, ultimately, the barrier provided by the NK cell to delay progression of AML is not sustained *in vivo*, such that no survival advantage is achieved by its presence. These data suggest that AML targets the NK cell early during disease progression to effectively evade its immune surveillance. Indeed, in both



**Figure 7. AML patients exhibit altered NK cell development.** Peripheral blood was obtained from untreated newly diagnosed AML patients or age- and sex-matched normal donors. NK cells were enriched by negative selection, labeled with anti-CD94, -CD56, -CD16, -CD3, -CD15, -CD64, -CD13, -CD3, -CD14, and -CD20, and then evaluated using highly selective gating by flow cytometry. “Bright” NK cells are defined as Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> cells. **(A)** Flow cytometry dot plot highlighting Bright NK cells in red rectangle from normal healthy donor and AML patient donor. **(B)** Percentage of Bright NK cells within the total NK cell population was evaluated in age-matched normal donors and AML patients ( $***P < 0.0001$ ;  $n = 10$  normal and  $n = 25$  untreated AML patients). **(C)** Additional samples of Bright NK cells taken from AML patients and normal donors were evaluated for T-bet expression by intracellular flow cytometry ( $***P < 0.0001$ ;  $n = 9$  normal donors and  $n = 5-9$  untreated AML patients). The data was first log<sub>2</sub> transformed and then ANOVA was used for analysis. **(D)** Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> cells were FACS-isolated from newly diagnosed untreated AML patients and normal controls. Levels of *Mir29b* were evaluated by real-time RT-PCR ( $**P = 0.006$ ;  $n = 13$  normal donors and  $n = 8$  untreated AML patients). A linear mixed modeling was used to determine the statistical difference between normal and AML patient samples (**B** and **D**).

the murine model and AML patients, we discovered a block in NK cell maturation that was associated with the progression of AML. An NK cell developmental intermediate population described as CD27<sup>+</sup>CD11b<sup>+</sup>, or DP, is nearly absent in leukemic mice, while NK cells accumulate at the earlier CD27 single-positive stage of maturation. We discovered a significant upregulation of miR-29b in the NK cells of leukemic mice, which downregulates expression of 2 transcription factors that are critical for NK cell maturation: T-bet and EOMES. Genetic disruption of the miR-29b loci restored the expression of EOMES in the CD27<sup>+</sup>CD11b<sup>+</sup> DP NK cell intermediate population that was adoptively transferred and led to a reversal in the leukemic-mediated depletion of this immature NK cell population. Importantly, untreated AML patients also exhibited a reduction in an intermediate Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> NK cell population, along with a decrease in T-bet and EOMES, and increased miR-29b expression in the CD56<sup>bright</sup> NK cell population. Notably, in both the mouse AML model and AML patients, we did still detect relatively normal percentages of terminally differentiated NK cells that are normally fully cytolytic; however, we showed that the content of perforin is depleted in mature NK cells in leukemic mice compared with nonleukemic mice and in some but not all of the few patients’ mature CD56<sup>dim</sup> NK cells that we were able to measure. This suggests a 2-pronged approach that AML is using to evade the NK cell’s innate immune surveil-

lance in vivo in addition to those already described: disarm the mature cytolytic effector cell by reducing its supply of perforin, and selectively eliminate the NK cell developmental intermediate that itself has noncytolytic functional capabilities as discussed below.

The observation of significantly reduced proliferation and decreased apoptosis in the NK cells found within leukemic mice may actually indicate a compensatory mechanism of survival that is implemented during a failure of normal differentiation. These observations are consistent with the idea that these cells may survive longer once they achieve terminal differentiation, but they may be less functional in vivo at this stage as suggested by our perforin and autologous cytotoxicity data and as suggested by others (34). Previous studies in AML have described AML blast resistance to binding of perforin granules, decreasing perforin-mediated lysis (37, 38), but an actual quantitative defect in perforin levels discovered in the most mature NK cell subset in vivo, as compared with normal NK cells, has not been observed until now. Recent studies by Khaznadar et al. suggest that low perforin expression in the less mature CD56<sup>bright</sup> NK cell population may contribute to a defective NK cell

functional phenotype in AML (39); however, this subset is normally noncytolytic (40). Dague et al. recently described an increase in CD56<sup>bright</sup> NK cells found when AML patients enter into complete remission, possibly indicative of early NK cell recovery once leukemic blasts are cleared (41).

The reduction in NK cell developmental intermediates seen in our study with the progression of AML was correlated at least in part with significantly reduced expression of the developmental transcription factors T-bet and EOMES in NK cells from leukemic mice and a significant reduction of T-bet in NK cells from AML patients. Previous studies in *Tbet* and *Eomes* KO mice have demonstrated the requirement of both transcription factors for terminal differentiation and functional activity of NK cells (21, 22). Mice lacking T-bet had fewer NK cells in their periphery, and these NK cells lacked the ability to differentiate into the final CD11b<sup>+</sup> stages of NK cell development. Gordon et al. expanded on these findings to demonstrate a complete loss of mature NK cells in mice lacking both *Tbet* and *Eomes* (22), supporting a role for both factors in NK cell generation. The *Eomes* KO mice also demonstrated an accumulation at the CD27<sup>+</sup>CD11b<sup>-</sup> stage of NK cell development, comparable to what was noted in NK cells from leukemic mice in the current study. However, contrary to the *Eomes* KO model, the NK cells in leukemic mice and in AML patients still retained NK cells in the final stage of terminal differentiation, suggesting that



a significant reduction of these transcription factors, rather than a complete loss, may allow for some final differentiation, and/or that alternate pathways of NK cell maturation may exist. In support of both possibilities, we used the murine AML model to show that the CD27<sup>+</sup>CD11b<sup>-</sup> developmental intermediary NK cell population preceding the nearly absent DP intermediary NK cell population was unable to proceed through normal differentiation *in vivo*. When our studies were expanded to untreated AML patients, the reduction in T-bet and EOMES protein expression was again observed within the less mature Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> NK cell population. While the reduction of T-bet and EOMES in AML patients was more modest than the reduction of these transcription factors in the AML mouse model, the AML mouse model represents a homogenous system while human AML is a heterogeneous disease. All untreated patients with the diagnosis of primary AML were included in this analysis. As the Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> NK cell population is the earliest precursor observed in appreciable numbers within human peripheral blood, we do not yet have the exact comparator in the human pathway to that which has been described in mice. The expression of CD27 and of CD11b was also evaluated on NK cells in AML patients, but no significant difference was found in these populations in the patient samples (Supplemental Figure 10). Additional studies are ongoing to determine the impact of AML on the development of NK cell precursors obtained from secondary lymphoid tissues where human NK cells develop (42). It would also be of interest to evaluate patients with myelodysplastic syndrome (MDS) to determine whether the Lin<sup>-</sup>CD56<sup>bright</sup>CD94<sup>+</sup>CD16<sup>-</sup> NK cell depletion precedes the development of overt AML in the MDS cases in which this progression to AML occurs.

To explore the mechanism(s) responsible for the reduction of both T-bet and EOMES expression, we evaluated common regulators of both transcription factors. miR-29b has been recently described as a direct regulator of both T-bet and EOMES in CD4<sup>+</sup> T cells (23, 27), but to our knowledge has not previously been evaluated in NK cells. We hypothesized that miR-29b may be altered by the leukemic environment and drive the changes in T-bet and EOMES in NK cells in leukemic mice. Indeed, we observed a significant upregulation of miR-29b expression in NK cells from leukemic mice. This established a possible mechanism for the reduced DP NK cells seen *in vivo*. Consistent with this model, when we adoptively transferred miR-29b KO NK cells into leukemic mice, unlike what was observed with WT NK cell transfer into leukemic mice, there was no reduction in the proportion of DP NK cells in comparison with nonleukemic recipient mice injected with the same cells. We also validated that both T-bet and EOMES expression was increased in the cells that were transplanted as compared with the WT littermate controls.

It is also interesting to note that before cell transfer there were more DP NK cell intermediates and fewer mature CD27<sup>+</sup>CD11b<sup>+</sup> NK cells in the miR-29 KO mice (Supplemental Figure 11). Likewise, this disproportion was again noted following adoptive transfer into leukemic mice (Figure 6C and not shown). This may be in part due to the higher EOMES expression in DP NK cells compared with the most mature CD27<sup>+</sup>CD11b<sup>+</sup> NK cell subset under normal homeostatic conditions (Figure 3E), or is more likely related to the inability of the AML cells to target an absent miR-29b following an infusion of miR-29b KO DP NK cells. Further studies would be

required to determine what role genetic disruption of miR-29b has in achieving terminal NK cell differentiation *in vivo*, and how this reversal of the NK cell phenotype *in vivo* affects progression of AML and/or overall survival. We would speculate that survival would not be altered significantly in such an aggressive and high-penetrance model of AML, given the multitude of mechanisms exhibited by AML to evade both the innate and antigen-specific components of the immune system, as discussed earlier. Indeed we do have data to suggest that while AML progression may be slowed by adoptive transfer of miR-29b KO NK cells in this model, this did not lead to a significant improvement in overall survival in preliminary studies (Supplemental Figure 8). This could be due to an exogenous source of miR-29b interacting with the transferred miR-29b KO NK cells, or alterations in homing of NK cells with altered miR-29b expression. Further studies will be needed to determine the precise role of miR-29b in modulating NK cell immunity in AML.

The finding of increased miR-29b in the NK cell compartment was unexpected, as low levels of miR-29b in the AML blast population have been previously associated with aggressive disease (43–45). Elevated levels in NK cells could be due in part to release of excessive miR-29b from AML blasts in the form of exosomes or vesicles, as this mechanism of cell-to-cell miR exchange has been reported in chronic leukemia (46, 47). Previous studies have established a role for extracellular vesicle trafficking in immune suppression and shedding of negative regulators of tumor cell growth or progression (46, 48–51). Interestingly, a recent study by Yeh et al. demonstrated that while there was no reduction in miR-29b expression between normal B cells and primary chronic lymphocytic leukemic (CLL) cells, there was a significant increase in miR-29b expression in exosomes derived from these primary CLL cells as compared with normal B cells (47). Indeed, preliminary studies in AML patients demonstrate the presence of miR-29b in the exosomes of patients with primary AML. Further, coculture of NK cells with plasma exosomes from patients with AML increases miR-29b in NK cells, compared with NK cells cocultured with plasma from normal individuals (data not shown). Alternatively, other soluble factors produced by either the leukemic blasts or the leukemic microenvironment could be regulating miR-29b expression in NK cells as well as other immune populations. For example, Smith et al. demonstrated that IFN- $\gamma$ , which was upregulated in cytokine-stimulated NK cells from leukemic mice *ex vivo*, has the ability to induce miR-29b in T cells (27). It is therefore possible that IFN- $\gamma$  is functioning as a negative-feedback loop to control NK cell development and alter mature NK cells *in vivo*, potentially skewing NK cells toward cell exhaustion and eventual hyporesponsiveness with chronic exposure to the leukemic microenvironment. Further studies would be required to determine what is specifically driving the overexpression of miR-29b in NK cells. One limitation of this work is the inability to evaluate miR-29b in the developmental NK cell precursor populations in human AML patients. NK cell sampling could be obtained prior to the disappearance of the DP NK cell population in the mouse model of AML.

As noted earlier, the presence of terminally differentiated mature NK cells in the mouse model of *de novo* AML and in AML patients requires additional investigation to determine what mechanisms allow for their persistence and/or generation despite the near absence of their developmental precursors. It could be that

alternate pathways of NK cell maturation are operative when developmental intermediates are selectively targeted for elimination. In support of this hypothesis, recent data presented by Wu et al. using genetic bar coding of CD34<sup>+</sup> progenitor populations in rhesus macaques indicated that CD56<sup>bright</sup> and CD56<sup>dim</sup> NK cells may arise from distinct progenitors (52). While there are ample data validating the maturation pathways established in both mice and humans (17, 18, 30, 53–56), it is possible if not likely that an additional undiscovered precursor exists, and the leukemic environment is shifting the balance that is seen under normal homeostatic conditions. Future studies would be warranted to determine whether the terminally differentiated NK cells as seen in our leukemic mice and patients arise from a noncanonical/distinct pathway.

Finally, and not inconsistent with the above, it could be that the developmental DP NK cell intermediate in the mouse has a critical as-yet unknown function distinct from killing that keeps AML in check, and the successful emergence of AML requires the elimination of this specific subset of innate immune effector cells in the same way that HIV selectively attacks the CD4 T helper cell subset. The consistency of our observation in both mice and humans would support this possibility. Indeed, unlike the cytolytic CD56<sup>dim</sup> NK cell found almost exclusively in peripheral blood, the less mature CD56<sup>bright</sup> human NK cell lives predominantly in the parafollicular T cell-rich region of secondary lymphoid tissue (19, 57). The CD56<sup>bright</sup> NK cell is a potent producer of cytokines, receiving signals for activation from dendritic cells residing in secondary lymphoid tissue and in turn priming other antigen-presenting cells with IFN- $\gamma$ , likely important for the antigen-specific arm of the immune system (57). As such, its selective absence in AML may have more to do with disarming T cell responsiveness to tumor-associated antigens than with NK cell maturation. Further investigation into defects in T cells or other immune subsets has yet to be explored in our murine model of AML but would be interesting given our findings with NK cell developmental alterations as AML progresses.

In summary, these studies have identified previously unknown NK cell defects in AML, and described a novel mechanism whereby miR dysregulation drives immune evasion through alterations in NK cell development. While the murine model uses the MLL-PTD and FLT3-ITD mutations to generate de novo AML, the alterations in NK cell maturation appear to occur across multiple different subtypes of AML, as our patients' molecular defects were not limited to MLL-PTD and/or FLT3-ITD disease. This suggests that the defects uncovered with these studies may represent a broad mechanism of targeting NK cell development to succeed with innate immune cell evasion in AML. Additional studies are underway to target this defect therapeutically and restore normal NK cell homeostasis. Further understanding of the forces driving this defect is also needed to effectively salvage NK cell development, and potentially improve NK cell-based therapies with the goal of preventing AML relapse.

## Methods

**Mouse strains.** All mice were bred and maintained in pathogen-free conditions, and all studies were approved by the Ohio State University Institutional Animal Care and Use Committee (IACUC). *MLL<sup>PTD/WT</sup> FLT3<sup>ITD/WT</sup>* (PTD/ITD) mice have been previously described (58). Congenic C57BL/6 *Rag2<sup>-/-</sup> Il2rg<sup>-/-</sup>* mice were purchased from Taconic Biosciences and were crossed with *MLL<sup>PTD/WT</sup> FLT3<sup>ITD/WT</sup>* mice to create *Rag2<sup>-/-</sup> Il2rg<sup>-/-</sup>*

*MLL<sup>PTD/WT</sup> FLT3<sup>ITD/WT</sup>* (PTD/ITD/Rag GC KO) mice. C57BL/6 *Mir29ab1<sup>-/-</sup>* mice were generated in house by S. Costinean and C.M. Croce (27, 59). Congenic CD45.1<sup>+</sup> C57BL/6 mice for transplant studies were obtained from Jackson Laboratory. All mice used in these studies were sex-matched and 6–12 weeks of age unless otherwise noted.

**AML transplantation.** For leukemic transplantation, CD45.2<sup>+</sup> leukemic cells were obtained from the spleens of primary leukemic mice (58). Recipient CD45.1<sup>+</sup> congenic mice were lethally irradiated (8 cGy) using an x-ray irradiator, and rescue bone marrow ( $1 \times 10^6$  cells per mouse) was provided at the time of leukemic transplantation. CD45.2<sup>+</sup> cells were injected i.v. into the irradiated recipients, and AML development was monitored by flow cytometry analysis of CD45.2 versus CD45.1 percentage positivity in the blood, as well as by wbc counts (Hemavet, Drew Scientific).

**NK cell isolation.** NK1.1<sup>+</sup>CD3<sup>-</sup> cells were isolated from spleens as previously described (60). NK cells were negatively enriched by magnetic microbead isolation (Miltenyi Biotec), followed by FACS using a BD FACS Aria II (BD Biosciences) to greater than 99% purity. NK cell subsets were isolated in the same manner, and purity was validated on each subset after sorting.

**Cell lines.** Yac-1 murine lymphoma and C1498 murine acute myeloid leukemia tumor cell lines were obtained from American Type Culture Collection. Both lines were maintained in RPMI 1640 with 10% FBS (Corning) and GlutaMAX (Gibco).

**Primary patient samples.** All human studies were conducted under an approved Ohio State University Institutional Review Board Protocol (2009C0019). Fresh peripheral blood samples from newly diagnosed, untreated AML patient samples were obtained through the Ohio State University Leukemia Tissue Bank. All newly diagnosed, untreated AML patients were accepted for study regardless of AML subtype. Normal donor peripheral blood was obtained through the American Red Cross (Columbus, Ohio, USA) or ZenBio. NK cells were enriched by negative selection with NK Rossette, containing anti-CD3, -CD4, -CD19, -CD36, -CD66b, and -CD123 antibodies, following the manufacturer's recommendations (Stem Cell Technologies). The blood was then layered over Ficoll-Paque PLUS (GE Healthcare) and centrifuged at 754 g for 20 minutes at room temperature. The NK cells were then collected from the enriched mononuclear layer. Red blood cells were lysed with ammonium chloride lysis buffer (Stem Cell Technologies), and single-cell suspensions were obtained. NK cells were labeled for immunophenotypic analysis as described below.

**Immunophenotypic analysis.** For multiparameter flow cytometry conducted on murine cells, single-cell suspensions were obtained from spleen, bone marrow, lymph node, or blood as previously described (58, 61). Briefly, organs were dissociated manually and washed with RPMI 1640 supplemented with 10% FBS and 0.5% EDTA, and rbc were lysed with ammonium chloride rbc lysis buffer (Stem Cell Technologies). Cells were resuspended in PBS supplemented with 2% FBS, labeled with the indicated antibodies for 30 minutes at 4°C, washed, and then analyzed on a BD LSRII flow cytometer (BD Biosciences). Human NK cells were labeled in the same manner. For intracellular staining, cells were labeled first with antibodies against cell surface antigens, then permeabilized with Cytotfix/Cytoperm (BD Biosciences), stained with antibodies against intracellular antigens, and suspended in 1% formalin before flow cytometry analyses. Data analysis was conducted with FlowJo version 7.6.5 software (Tree Star). A list of all antibody clones used in these studies can be found in Supplemental Table 1.

**In vivo cell proliferation assay.** Murine NK cells were obtained from spleens as described above, isolated by FACS, and labeled with 10  $\mu$ M Cell Proliferation Dye eFluor 670 (eBioscience) according to the manufacturer's protocol. Proliferation was calculated by taking gating on peaks indicating cell division within the total Cell Proliferation Dye-positive population. NK cells were transplanted into mice or placed in culture to control for flow cytometry evaluation after mouse harvesting. NK cells in culture were maintained in RPMI 1640 supplemented with 20% FBS (Corning), 1% antibiotic/antimycotic (Life Technologies), 55  $\mu$ M 2-mercaptoethanol (Life Technologies), and IL-2 (100 ng/ml; Peprotech).

**In vivo apoptosis assay.** The commercially available FAM-FLUORESCENCE IN VIVO (FAM-FLIVO) in vivo apoptosis kit was used to determine level of apoptosis in leukemic and WT mice (ImmunoChemistry Technologies). The manufacturer's instructions were followed. Briefly, mice were injected i.v. with 8  $\mu$ g/mouse FAM-FLIVO reagent. After 60 minutes, mice were harvested and cells were isolated for flow cytometry analysis. Additional cell surface antigens were evaluated to determine the level of apoptosis in specific NK cell populations.

**Adoptive transfer experiments.** Murine NK cells or NK cell subsets were isolated as described, sorted by FACS to greater than 99% purity, and injected i.v. into nonleukemic or leukemic recipient mice. Congenic CD45.1<sup>+</sup> cells were used for transfer experiments, and/or cells were labeled with Cell Proliferation Dye eFluor 670 (eBioscience) for short-term studies. Purity was validated before mouse injection.

**IFN- $\gamma$  production.** Freshly isolated splenocytes were obtained from leukemic and nonleukemic mice and incubated with plate-bound anti-NK1.1 (15  $\mu$ g/ml) or isotype control for 6 hours in the presence of GolgiStop (BD Biosciences); labeled with anti-NK1.1, -CD3, and -CD45.1 surface antibodies; then fixed, permeabilized, and labeled with anti-IFN- $\gamma$  antibody and evaluated by intracellular flow cytometry. For soluble IFN- $\gamma$  production, murine NK cells were obtained from spleens of nonleukemic or leukemic mice and isolated by FACS sorting to purity greater than 99%, and were placed into culture. Cells were left unstimulated or stimulated with IL-12 (20 ng/ml; Genetics Institute Inc.) plus IL-18 (10 ng/ml; R&D Systems) for 24 hours *ex vivo* in RPMI 1640 supplemented with 10% FBS (Corning) and 55  $\mu$ M 2-mercaptoethanol (Life Technologies). Supernatants were harvested and soluble IFN- $\gamma$  was quantitated according to the manufacturer's instructions using a commercially available kit (R&D Systems).

**Cytotoxicity assays.** Yac-1, C1498, or autologous blasts were used as targets where indicated in a standard 4-hour chromium release assay with freshly isolated murine NK cells as effectors as previously described (60).

**Quantitative real-time RT-PCR.** RNA was isolated from NK cells using the Total RNA Purification Kit Plus (Norgen Biotek). cDNA was then obtained using the SuperScript VILO Master Mix (Life Technologies). Quantitative PCR was performed using either predesigned TaqMan probes or primers with SYBR Green Master Mix (Life Technologies) using a ViiA 7 real-time PCR system (Life Technologies). *Tbx21*, *Eomes*, and *Gapdh* (internal control) SYBR Green primers were obtained from Sigma-Aldrich as previously described (62), and microRNA-29b

(000413 murine and human miR-29b) and U6 control (001973 U6 for mouse; 001094 RNU44 for human) TaqMan primer/probes were purchased commercially (Life Technologies). Gene expression was normalized to an internal control ( $\Delta$ Ct = Ct gene of interest - Ct internal control). Relative mRNA expression for each gene tested was calculated as  $2^{-\Delta\Delta Ct}$ . For miR-29b expression in patients and normal controls, the average  $\Delta$ Ct was calculated for the normal control samples. Relative mRNA expression for each patient and normal donor was calculated based on this average  $\Delta$ Ct and reported as relative fold change.

**Statistics.** Statistical significance was determined with Student's *t* test, 2-tailed, for single comparisons, or linear mixed effects models were used for multiple comparisons to take account of correlations among observations from the same mouse. Holm's procedure was used to adjust for multiple comparisons. After adjustment for multiple comparisons, *P* values less than 0.05 were considered significant. Bar graphs are presented as mean  $\pm$  SEM unless otherwise noted. Log-rank test analysis was used for survival comparisons *in vivo*. SAS 9.3 (SAS Institute Inc.) and GraphPad Prism software were used for analysis.

**Study approval.** All murine studies were conducted under the approved Ohio State IACUC protocol 2009A0033-R2. For all human studies, written informed consent was received from participants prior to inclusion in the study where required. All samples were obtained under the approved IRB protocol 2009C0019.

## Author contributions

BLM, with the help of SDS, JY, AGF, and MAC, designed experiments, analyzed the data, and wrote the manuscript. BLM, LC, KM, EHA, NZ, JC, and SH performed experiments and analyzed data. XZ helped with statistical design and analysis. SC and CMC provided expertise with miR-29b murine studies and participated in the preparation of the manuscript. KL and JCB assisted with human miR-29b studies and participated in the preparation of the manuscript. HCM helped with flow cytometry design and analysis. SV and WB procured AML patient samples and participated in the preparation of the manuscript.

## Acknowledgments

This work was supported by NIH National Cancer Institute grants CA89341, CA095426, CA163205, CA016058, and CA068458 (to MAC); CA9338-36 (to BLM); and F30CA196244 (to SDS). We gratefully acknowledge the use of the Ohio State University Comprehensive Cancer Center (OSUCCC) Analytical Cytometry Shared Resource and the AML cells provided by the OSUCCC Leukemia Tissue Bank Shared Resource, which is supported by NIH National Cancer Institute P30CA016058.

Address correspondence to: Michael A. Caligiuri, Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute, The Ohio State University, 460 W. 10th Avenue, Suite D920, Columbus, Ohio 43210, USA. Phone: 614.293.7521; E-mail: michael.caligiuri@osumc.edu.

1. SEER Cancer Statistics Review, 1975-2012. National Cancer Institute. [http://seer.cancer.gov/csr/1975\\_2012](http://seer.cancer.gov/csr/1975_2012). Published April 2015. Accessed September 20, 2016.
2. Yu J, Freud AG, Caligiuri MA. Location and cel-

- ular stages of natural killer cell development. *Trends Immunol.* 2013;34(12):573-582.
3. Miller JS, et al. Successful adoptive transfer and *in vivo* expansion of human haploidentical NK cells in patients with cancer. *Blood.*

2005;105(8):3051-3057.

4. Ruggeri L, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science.* 2002;295(5562):2097-2100.

5. Tratkiewicz JA, Szer J. Loss of natural killer activity as an indicator of relapse in acute leukaemia. *Clin Exp Immunol.* 1990;80(2):241-246.
6. Pross HF, Lotzová E. Role of natural killer cells in cancer. *Nat Immun.* 1993;12(4-5):279-292.
7. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. *Leukemia.* 1996;10(3):478-482.
8. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. *Leukemia.* 2012;26(9):2019-2026.
9. Salih HR, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. *Blood.* 2003;102(4):1389-1396.
10. Diermayr S, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. *Blood.* 2008;111(3):1428-1436.
11. Cooley S, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. *Blood.* 2010;116(14):2411-2419.
12. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. *Blood.* 2009;114(8):1545-1552.
13. Ahmad SM, Svane IM, Andersen MH. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. *Blood Cancer J.* 2014;4:e230.
14. Zhong RK, Loken M, Lane TA, Ball ED. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. *Cytotherapy.* 2006;8(1):3-12.
15. Nguyen S, et al. HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytotoxicity after haplo-mismatched hematopoietic SCT. *Bone Marrow Transplant.* 2009;43(9):693-699.
16. Benson DM, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. *Blood.* 2012;120(22):4324-4333.
17. Hayakawa Y, Smyth MJ. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. *J Immunol.* 2006;176(3):1517-1524.
18. Chiossone L, Chaix J, Fuseri N, Roth C, Vivrier E, Walzer T. Maturation of mouse NK cells is a 4-stage developmental program. *Blood.* 2009;113(22):5488-5496.
19. Caligiuri MA. Human natural killer cells. *Blood.* 2008;112(3):461-469.
20. Freud AG, Yu J, Caligiuri MA. Human natural killer cell development in secondary lymphoid tissues. *Semin Immunol.* 2014;26(2):132-137.
21. Townsend MJ, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. *Immunity.* 2004;20(4):477-494.
22. Gordon SM, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. *Immunity.* 2012;36(1):55-67.
23. Steiner DF, et al. MicroRNA-29 regulates T-box transcription factors and interferon- $\gamma$  production in helper T cells. *Immunity.* 2011;35(2):169-181.
24. Sullivan RP, et al. MicroRNA-15/16 antagonizes Myb to control NK cell maturation. *J Immunol.* 2015;195(6):2806-2817.
25. Ma F, et al. The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon- $\gamma$ . *Nat Immunol.* 2011;12(9):861-869.
26. Leong JW, Sullivan RP, Fehniger TA. microRNA management of NK-cell developmental and functional programs. *Eur J Immunol.* 2014;44(10):2862-2868.
27. Smith KM, et al. miR-29ab1 deficiency identifies a negative feedback loop controlling Th1 bias that is dysregulated in multiple sclerosis. *J Immunol.* 2012;189(4):1567-1576.
28. Bernot KM, et al. Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. *Blood.* 2013;122(23):3778-3783.
29. Costello RT, et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. *Blood.* 2002;99(10):3661-3667.
30. Dulphy N, et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. *J Immunol.* 2008;181(3):2227-2237.
31. Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. *Leukemia.* 2005;19(12):2215-2222.
32. Kim S, et al. In vivo developmental stages in murine natural killer cell maturation. *Nat Immunol.* 2002;3(6):523-528.
33. Huntington ND, et al. NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. *J Immunol.* 2007;178(8):4764-4770.
34. Stringaris K, et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. *Haematologica.* 2014;99(5):836-847.
35. Fauriat C, et al. Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. *Blood.* 2007;109(1):323-330.
36. Baessler T, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. *Cancer Res.* 2009;69(3):1037-1045.
37. Otten HG, van Ginkel WG, Hagenbeek A, Petersen EJ. Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia. *Leukemia.* 2004;18(8):1401-1405.
38. Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. *Blood.* 2000;96(2):594-600.
39. Khaznadar Z, et al. Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion. *J Immunol.* 2015;195(6):2580-2590.
40. Cooper MA, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. *Blood.* 2001;97(10):3146-3151.
41. Dauguet N, Récher C, Demur C, Fournié JJ, Pouput M, Pouput R. Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission. *Am J Hematol.* 2011;86(2):209-213.
42. Freud AG, Caligiuri MA. Human natural killer cell development. *Immunol Rev.* 2006;214:56-72.
43. Garzon R, et al. MicroRNA 29b functions in acute myeloid leukemia. *Blood.* 2009;114(26):5331-5341.
44. Garzon R, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. *Blood.* 2008;111(6):3183-3189.
45. Liu S, et al. Sp1/NFkB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. *Cancer Cell.* 2010;17(4):333-347.
46. Huan J, et al. RNA trafficking by acute myelogenous leukemia exosomes. *Cancer Res.* 2013;73(2):918-929.
47. Yeh YY, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. *Blood.* 2015;125(21):3297-3305.
48. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). *PLoS One.* 2010;5(7):e11469.
49. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor- $\beta$ 1. *Haematologica.* 2011;96(9):1302-1309.
50. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). *Biochem Soc Trans.* 2013;41(1):245-251.
51. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. *J Immunol.* 2008;180(11):7249-7258.
52. Wu C, et al. Clonal tracking of rhesus macaque hematopoiesis highlights a distinct lineage origin for natural killer cells. *Cell Stem Cell.* 2014;14(4):486-499.
53. Huntington ND, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. *J Exp Med.* 2009;206(1):25-34.
54. Lopez-Vergès S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. *Blood.* 2010;116(19):3865-3874.
55. Romagnani C, et al. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. *J Immunol.* 2007;178(8):4947-4955.
56. Yu J, et al. CD94 surface density identifies a func-

- tional intermediary between the CD56bright and CD56dim human NK-cell subsets. *Blood*. 2010;115(2):274–281.
57. Fehniger TA, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. *Blood*. 2003;101(8):3052–3057.
58. Zorko NA, et al. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. *Blood*. 2012;120(5):1130–1136.
59. Cushing L, et al. Disruption of miR-29 leads to aberrant differentiation of smooth muscle cells selectively associated with distal lung vasculature. *PLoS Genet*. 2015;11(5):e1005238.
60. Trotta R, et al. Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. *Blood*. 2013;121(16):3126–3134.
61. Trotta R, et al. miR-155 regulates IFN- $\gamma$  production in natural killer cells. *Blood*. 2012;119(15):3478–3485.
62. Deng Y, et al. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. *Immunity*. 2015;42(3):457–470.